Targets › FUS
1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Mar 2028.
DNA/RNA-binding protein that plays a role in various cellular processes such as transcription regulation, RNA splicing, RNA transport, DNA repair and damage response. Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3'. Binds to nascent pre-mRNAs and acts as a molecular mediator between RNA polymerase II and U1 small nuclear ribonucleoprotein thereby coupling transcription and splicing. (UniProt, P35637)
Open in Phaseline: the race on FUS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals | ION363 Antisense oligonucleotide targeting FUS mRNA | FUS | Phase 3 | Amyotrophic Lateral Sclerosis | Mar 2028 |
Amyotrophic Lateral Sclerosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.